Gentherm Medical announced U.S. Food and Drug Administration 510(k) clearance for the ThermAffyx Patient Safety System, a Class II medical device that combines active patient warming, patient securement and pressure reduction into a single platform. Gentherm provides thermal management and pneumatic comfort technologies and said the clearance expands its patient temperature management portfolio.
Surgical teams have traditionally used separate products to keep patients warm and to prevent intraoperative shifting. Gentherm noted that conventional underbody securement pads provide anti-slip function but do not deliver active warming. That separation can matter most in robotic-assisted surgery, where steep positioning, surgical draping and robotic equipment limit access to the patient.
The company cited published research indicating that during these procedures only about 17% to 21% of a patient’s body surface area may be available for conventional forced-air warming. Gentherm also reported that despite the use of warming interventions, more than one-quarter of robotic surgery patients are hypothermic on arrival to recovery. Those points framed Gentherm’s rationale for integrating warming into an underbody securement surface rather than relying on blankets or separate warming devices.
ThermAffyx embeds active underbody warming directly into an anti-slip securement pad, creating a combined warming and securement surface. The system features a radiolucent heating element intended not to interfere with intraoperative imaging. Gentherm said the heating element is powered by its proprietary Carbotex carbon-fiber heating technology.
Gentherm described the device as a patient safety platform tailored to the workflow demands of modern robotic surgery, where extended procedure times, fixed positioning and limited access to the patient can increase thermoregulation risk.
Inadvertent perioperative hypothermia has been linked to surgical complications such as higher surgical site infection rates, coagulopathy, longer post-anesthesia recovery and increased intraoperative blood loss. Professional guidelines from anesthesiology and perioperative nursing organizations have called for active temperature monitoring and warming as standard practice for most procedures under general or neuraxial anesthesia lasting longer than 30 minutes.
Robotic-assisted platforms complicate that standard because steep positioning, robotic arms, port placements and draping often cover body areas that would otherwise be reachable with forced-air warming blankets. Device developers have responded by integrating warming into surfaces that patients already contact—underbody pads, positioning devices and table surfaces—rather than relying on top-layer blankets.
The broader medical device market has trended toward combining single-function OR products into integrated platforms. Gentherm positioned ThermAffyx within that trend, saying a consolidated device can simplify hospital purchasing, training and supply-chain decisions. Hospitals facing staffing constraints and turnover-time pressures are increasingly evaluating new OR technology on its ability to reduce setup steps and equipment rather than solely on clinical performance.
By offering warming, securement and pressure reduction in one product, Gentherm argued ThermAffyx could reduce the number of separate devices perioperative teams must manage for robotic procedures.
Gentherm noted the system is designed for the more than 3 million robotic-assisted surgical procedures performed annually worldwide. The company said product trials at healthcare facilities are scheduled to begin in August, with revenue generation expected to start in the third quarter of 2026.
The FDA 510(k) clearance allows Gentherm to market ThermAffyx as a Class II device that integrates warming and securement functions. The source reported the device’s key design features and planned commercial steps but did not provide detailed clinical study results, comparative effectiveness data, pricing, reimbursement plans or which specific hospitals will host product trials.
As robotic surgery volumes continue to grow across specialties such as general surgery, urology and gynecology, manufacturers are likely to pursue integrated patient-safety platforms that address the unique ergonomic and positioning challenges of these procedures. Gentherm’s ThermAffyx represents one approach that embeds warming where patients are already positioned, potentially changing how perioperative teams manage temperature control during robotic cases.
How quickly individual hospitals adopt the system will depend on trial outcomes, purchasing decisions, training and whether the integrated platform reduces steps and equipment burden compared with separate warming and securement products. The source article did not report on trial timelines beyond the August start, specific evaluation metrics to be used during trials, or expected sales volumes.
The FDA 510(k) clearance for Gentherm’s ThermAffyx Patient Safety System establishes an integrated option that combines active warming with anti-slip securement and pressure reduction for robotic-assisted surgery. Gentherm has scheduled product trials to begin in August and expects revenue in the third quarter of 2026. The device aims to address gaps in warming access created by robotic positioning and draping, and it fits within a broader industry move toward multifunctional operating room platforms.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.